Recently, licensed and emerging treatments for metastatic castrate-resistant prostate cancer are transforming the prognosis for men whose disease has already progressed during or after docetaxel ...

"Our study demonstrates the critical role of PSMA-PET in accurately staging prostate cancer, which can significantly impact treatment decisions and outcomes," said senior author of the study Dr ...

Androgen deprivation is the mainstay of advanced prostate cancer treatment. Despite initial ... Intravenous; mCRPC: Metastatic castration-resistant prostate cancer; P: Placebo; PSA: Prostate ...

"Our study demonstrates the critical role of PSMA-PET in accurately staging prostate cancer, which can significantly impact treatment decisions and outcomes," said senior author of the study Dr ...

PSMA-PET/CT findings were positive in 84% of the patients. PSMA-PET/CT detected distant metastatic disease in 46% of patients, including 34% of patients after RP, 56% after definitive RT, and 60% ...

High intensity focused ultrasound (HIFU) is a novel prostate cancer treatment that minimizes side effect while destroying ...

Not only did the treatment effectively deliver MSB to the prostate ... To characterize this pathway, the researchers used CRISPR-Cas9 screens on two metastatic prostate cancer cell lines to identify ...

In 2024, Feng received the “Mentorship Award” from ASTRO. In December, the American Society for Clinical Oncology (ASCO) ...

This follows the initial licence for treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in 2020. Following entry into a commercial agreement with Bayer ...

The study, published in JAMA Network Open, found that nearly half of high-risk prostate cancer patients previously classified as nonmetastatic by conventional imaging actually have metastatic disease ...